Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
BIOCON ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-23 |
ACTAVIS Dec-18 |
BIOCON / ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 388 | 16,159 | - | |
Low | Rs | 192 | 10,840 | - | |
Sales per share (Unadj.) | Rs | 93.1 | 3,963.8 | - | |
Earnings per share (Unadj.) | Rs | 5.4 | -1,276.8 | - | |
Cash flow per share (Unadj.) | Rs | 14.6 | 417.7 | - | |
Dividends per share (Unadj.) | Rs | 1.50 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 146.5 | 16,349.0 | - | |
Shares outstanding (eoy) | m | 1,200.60 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.1 | 3.4 | 91.4% | |
Avg P/E ratio | x | 54.1 | -10.6 | -511.6% | |
P/CF ratio (eoy) | x | 19.8 | 32.3 | 61.3% | |
Price / Book Value ratio | x | 2.0 | 0.8 | 239.4% | |
Dividend payout | % | 28.0 | 0 | - | |
Avg Mkt Cap | Rs m | 347,814 | 4,489,898 | 7.7% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 21,810 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 78,010.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,127.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 111,742 | 1,318,372 | 8.5% | |
Other income | Rs m | 7,681 | 25,212 | 30.5% | |
Total revenues | Rs m | 119,423 | 1,343,584 | 8.9% | |
Gross profit | Rs m | 16,611 | 34,548 | 48.1% | |
Depreciation | Rs m | 11,131 | 563,576 | 2.0% | |
Interest | Rs m | 4,190 | 76,078 | 5.5% | |
Profit before tax | Rs m | 8,971 | -579,893 | -1.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,896 | 0.0% | |
Tax | Rs m | 2,541 | -7,349 | -34.6% | |
Profit after tax | Rs m | 6,430 | -424,648 | -1.5% | |
Gross profit margin | % | 14.9 | 2.6 | 567.3% | |
Effective tax rate | % | 28.3 | 1.3 | 2,235.1% | |
Net profit margin | % | 5.8 | -32.2 | -17.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 123,340 | 540,727 | 22.8% | |
Current liabilities | Rs m | 85,107 | 478,345 | 17.8% | |
Net working cap to sales | % | 34.2 | 4.7 | 723.1% | |
Current ratio | x | 1.4 | 1.1 | 128.2% | |
Inventory Days | Days | 129 | 20 | 658.8% | |
Debtors Days | Days | 117 | 66 | 176.0% | |
Net fixed assets | Rs m | 394,078 | 149,232 | 264.1% | |
Share capital | Rs m | 6,003 | 0 | - | |
Net worth | Rs m | 175,929 | 5,437,670 | 3.2% | |
Long term debt | Rs m | 152,905 | 1,914,801 | 8.0% | |
Total assets | Rs m | 517,418 | 8,500,316 | 6.1% | |
Interest coverage | x | 3.1 | -6.6 | -47.4% | |
Debt to equity ratio | x | 0.9 | 0.4 | 246.8% | |
Sales to assets ratio | x | 0.2 | 0.2 | 139.2% | |
Return on assets | % | 2.1 | -4.1 | -50.1% | |
Return on equity | % | 3.7 | -7.8 | -46.8% | |
Return on capital | % | 4.0 | -4.8 | -82.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,525 | 471,005 | 3.9% | |
From Investments | Rs m | -142,818 | 258,756 | -55.2% | |
From Financial Activity | Rs m | 130,487 | -808,385 | -16.1% | |
Net Cashflow | Rs m | 6,411 | -78,232 | -8.2% |
Compare BIOCON With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare BIOCON With: THEMIS MEDICARE GENNEX LAB. LASA SUPERGENERICS SHELTER PHARMA WYETH
Asian markets traded lower on Friday tracking overnight losses on Wall Street and inflation data from Japan.